Research progress in the influence of EGFR genovariation on the clinical efficacy of gefitinib treatment of non-small cell lung cancer

摘要

As an epidermal growth factor receptor (EGFR) tyrosine kinase lung cancer-targeted drug, gefitinib has been widely applied in the treatment of non-small cell lung cancer (NSCLC). The present clinical application has shown that EGFR genovariation might cause the abnormal expression of lung cancer cells, it makes its sensibility to gefitinib decrease, and the clinical efficacy will be decreasing accordingly. Based on these problems, the effects of EGFR genovariation on the clinical efficacy of gefitinib treatment of NSCLC was further analyzed, and the successive development was summarized.